New analysis shows survival benefit of Novartis' Kisqali
admin 27th May 2020 Uncategorised 0In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials
More: New analysis shows survival benefit of Novartis' Kisqali
Source: News